Back to resultsGenetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD
Primary Purpose
Glaucoma
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Assessing the blood level of cholesterol 24 S Hydroxylase
Assessing the blood level of cholesterol 24 S hydroxylase
assessing the blood level of cholesterol 24 S hydroxylase
Sponsored by
About this trial
This is an interventional screening trial for Glaucoma
Eligibility Criteria
Inclusion Criteria:
- Patient with Glaucoma
- Patient with AMD
- Healthy patient
Exclusion Criteria:
- All patients who use any treatment in order to maintain in normal value their blood cholesterol
Sites / Locations
- Ophthalmology Unit CHU Dijon
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
G
AMD
Healthy subjects
Arm Description
Outcomes
Primary Outcome Measures
To know if cholesterol 24 S hydroxylase and 24 hydroxycholesterol are involve in Glaucoma and AMD
Secondary Outcome Measures
Full Information
NCT ID
NCT00629044
First Posted
February 25, 2008
Last Updated
March 25, 2011
Sponsor
Centre Hospitalier Universitaire Dijon
1. Study Identification
Unique Protocol Identification Number
NCT00629044
Brief Title
Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD
Official Title
Etude du Polymorphysme génétique de la cholestérol 24S Hydroxylase et Des Teneurs en 24S hydroxycholestérol Chez Des Patients Atteints de Glaucome ou de dégénérescence Maculaire liée à l'âge.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2009
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
November 2009 (Actual)
Study Completion Date
January 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Centre Hospitalier Universitaire Dijon
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to assess the implicitement of the cholesterol 24 S hydroxylase gene and the 24 S hydroxycholesterol in glaucoma and in age related macular degeneration.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
320 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
G
Arm Type
Active Comparator
Arm Title
AMD
Arm Type
Active Comparator
Arm Title
Healthy subjects
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
Assessing the blood level of cholesterol 24 S Hydroxylase
Intervention Description
Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
Intervention Type
Biological
Intervention Name(s)
Assessing the blood level of cholesterol 24 S hydroxylase
Intervention Description
Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
Intervention Type
Biological
Intervention Name(s)
assessing the blood level of cholesterol 24 S hydroxylase
Intervention Description
Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
Primary Outcome Measure Information:
Title
To know if cholesterol 24 S hydroxylase and 24 hydroxycholesterol are involve in Glaucoma and AMD
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patient with Glaucoma
Patient with AMD
Healthy patient
Exclusion Criteria:
All patients who use any treatment in order to maintain in normal value their blood cholesterol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Catherine Creuzot-Gracher, MD, PhD
Organizational Affiliation
CHU Dijon
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ophthalmology Unit CHU Dijon
City
Dijon
State/Province
Burgundy
ZIP/Postal Code
21000
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
18156378
Citation
Joffre C, Souchier M, Gregoire S, Viau S, Bretillon L, Acar N, Bron AM, Creuzot-Garcher C. Differences in meibomian fatty acid composition in patients with meibomian gland dysfunction and aqueous-deficient dry eye. Br J Ophthalmol. 2008 Jan;92(1):116-9. doi: 10.1136/bjo.2007.126144.
Results Reference
background
Learn more about this trial
Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD
We'll reach out to this number within 24 hrs